Original Report| Volume 17, ISSUE 6, P745-752, June 2016

Analysis of the Abuse and Diversion of the Buprenorphine Transdermal Delivery System


      • Abuse and diversion of the BTDS was low compared with other extended release opioids.
      • Abuse and diversion of the BTDS was low by both population and prescription rates.
      • Abuse and diversion of the BTDS was low compared with other buprenorphine products.


      Prescription opioid abuse and diversion are major causes of morbidity and mortality in the United States. The buprenorphine transdermal delivery system (BTDS) is indicated for the treatment of moderate to severe chronic pain and provides a continuous dose of 5, 7.5, 10, 15, or 20 μg/h buprenorphine for 7 days. Quarterly rates of abuse and diversion of BTDS were compared with 4 comparator groups: 1) other buprenorphine products, 2) fentanyl patches, 3) extended-release (ER) opioid tablets/capsules, and 4) ER tramadol. Data were obtained from the Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS) System Poison Center, Drug Diversion, Treatment Programs Combined (Opioid Treatment and Survey of Key Informants’ Patients Programs), and College Survey Programs. Rates were calculated using case counts per population and mentions per prescriptions filled. Poisson regression analysis was used to compare mean rates over time across drug groups after allowing for drug group-specific dispersion parameters. Population adjusted abuse rates were low for BTDS in all of the RADARS System programs compared with the other comparator groups. Findings were similar for the prescription adjusted rates, with BTDS reported at the lowest rates in all programs. Route of abuse differed slightly for BTDS and the comparator groups depending on the program. BTDS was abused and diverted at low rates compared with the other opioid groups in 5 programs of the RADARS System using either population-based rates or prescription dispensed rates.


      Data from the RADARS System show the BTDS is abused and diverted at low rates compared with other opioid groups including other forms of buprenorphine, fentanyl patches, ER opioid formulations, and ER tramadol.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The Journal of Pain
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Bazazi A.R.
        • Yokell M.
        • Fu J.J.
        • Rich J.D.
        • Zaller N.D.
        Illicit use of buprenorphine/naloxone among injecting and non-injecting opioid users.
        J Addict Med. 2011; 5: 175-180
      1. Butrans [package insert]. Purdue Pharma Inc, Stamford, CT2015
        • Cicero T.J.
        • Dart R.C.
        • Inciardi J.A.
        • Woody G.E.
        • Schnoll S.
        • Munoz A.
        The development of a comprehensive risk-management program for prescription opioid analgesics: Researched abuse, diversion and addiction-related surveillance (RADARS).
        Pain Med. 2007; 8: 157-170
        • Daniulaityte R.
        • Falck R.
        • Carlson R.G.
        Illicit use of buprenorphine in a community sample of young adult non-medical users of pharmaceutical opioids.
        Drug Alcohol Depend. 2012; 122: 201-207
        • Dart R.C.
        • Bartelson B.B.
        • Adams E.H.
        Non-medical use of Tapentadol Immediate Release by college students.
        Clin J Pain. 2014; 30: 685-692
        • Dasgupta N.
        • Bailey E.J.
        • Cicero T.
        • Inciardi J.
        • Parrino M.
        • Rosenblum A.
        • Dart R.C.
        Post-marketing surveillance of methadone and buprenorphine in the United States.
        Pain Med. 2010; 11: 1078-1091
        • Dasgupta N.
        • Freifeld C.
        • Brownstein J.S.
        • Menone C.M.
        • Surratt H.L.
        • Poppish L.
        • Green J.L.
        • Lavonas E.J.
        • Dart R.C.
        Crowdsourcing black market prices for prescription opioids.
        J Med Internet Res. 2013; 15: e178
        • Davis J.M.
        • Severtson S.G.
        • Bucher-Bartelson B.
        • Dart R.C.
        Using poison center exposure calls to predict prescription opioid abuse and misuse-related emergency department visits.
        Pharmacoepidemiol Drug Saf. 2014; 23: 18-25
        • Inciardi J.A.
        • Surratt H.L.
        • Lugo Y.
        • Cicero T.J.
        The diversion of prescription opioid analgesics.
        Law Enforc Exec Forum. 2007; 7: 127-141
        • Lanier R.K.
        • Umbricht A.
        • Harrison J.A.
        • Nuwayser E.S.
        • Bigelow G.E.
        Opioid detoxification via single 7-day application of a buprenorphine transdermal patch: An open-label evaluation.
        Psychopharmacology. 2008; 198: 149-158
        • Lavonas E.J.
        • Severtson S.G.
        • Martinez E.M.
        • Bucher-Bartelson B.
        • Le Lait M.C.
        • Green J.L.
        • Murrelle L.E.
        • Cicero T.J.
        • Kurtz S.P.
        • Rosenblum A.
        • Surratt H.L.
        • Dart R.C.
        Abuse and diversion of buprenorphine sublingual tablets and film.
        J Subst Abuse Treat. 2014; 47: 27-34
        • Paulozzi L.
        • Dellinger A.
        • Degutis L.
        Lessons from the past.
        Inj Prev. 2012; 18: 70
        • Przeklasa-Muszynska A.
        • Dobrogowski J.
        Transdermal buprenorphine for the treatment of moderate to severe chronic pain: Results from a large multicenter, non-interventional post-marketing study in Poland.
        Curr Med Res Opin. 2011; 27: 1109-1117
        • Sansone R.A.
        • Sansone L.A.
        Buprenorphine treatment for narcotic addiction: Not without risks.
        Innov Clin Neurosci. 2015; 12: 32-36
        • Sembower M.A.
        • Ertischek M.D.
        • Buchholtz C.
        • Dasgupta N.
        • Schnoll S.H.
        Surveillance of diversion and nonmedical use of extended-release prescription amphetamine and oral methylphenidate in the United States.
        J Addict Dis. 2013; 32: 26-38
        • Severtson S.G.
        • Bucher Bartelson B.
        • Davis J.M.
        • Munoz A.
        • Schneider M.F.
        • Chilcoat H.
        • Coplan P.M.
        • Surratt H.
        • Dart R.C.
        Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010.
        J Pain. 2013; 14: 1122-1130
        • Sporer K.A.
        Buprenorphine: A primer for emergency physicians.
        Ann Emerg Med. 2004; 43: 580-584
        • Substance Abuse and Mental Health Services Administration
        Results from the 2011 National Survey on Drug Use and Health: Summary of National Findings.
        (NSDUH Series H-44, HHS Publication No. (SMA) 12–4713) Substance Abuse and Mental Health Services Administration, Rockville, MD2012
        • Substance Abuse and Mental Health Services Administration
        The Dawn Report: Highlights of the 2010 Drug Abuse Warning Network (DAWN) Findings on Drug-Related Emergency Department Visits.
        Substance Abuse and Mental Health Services Administration, Rockville, MD2012
        • Wadhwa R.
        • Chilkoti G.
        • Saxena A.K.
        Current clinical opinions, attitudes and awareness of interns regarding post-operative and cancer pain management in a tertiary care centre.
        Indian J Palliat Care. 2015; 21: 49-55
      2. Warner M, Chen LH, Makuc DM. Increase in fatal poisonings involving opioid analgesics in the United States, 1999-2006. NCHS Data Brief 1-8, 2009

        • Wightman R.
        • Perrone J.
        • Portelli I.
        • Nelson L.
        Likeability and abuse liability of commonly prescribed opioids.
        J Med Toxicol. 2012; 8: 335-340
      3. World Health Organization Expert Committee on Drug Dependence: WHO Expert Committee on Drug Dependence. World Health Organ Tech Rep Ser 915:i-v, 1–26, back cover, 2003

        • Zosel A.
        • Bartelson B.B.
        • Bailey E.
        • Lowenstein S.
        • Dart R.
        Characterization of adolescent prescription drug abuse and misuse using the Researched Abuse Diversion and Addiction-related Surveillance (RADARS) System.
        J Am Acad Child Adolesc Psychiatry. 2013; 52: 196-204.e2